Replies to post #686 on Clinuvel Pharmaceuticals (CLVLY)

[FarmaZutical]

If you only look at the first indication, EPP, and estimate 4000 patients across Europe, USA, Australia and Japan (conservative total estimate) then we could be looking at $ 240 million in revenues and ~$50-60 pps at a 20 ratio.

Now, EPP might be financially interesting but in the medium to long run not that much.

Once the FDA has approved Scenesse, we will hopefully hear about Vitiligo ph3, cosmetics, Variegate Porphyria, Xeroderma Pigmentosum, a-Msh lotions and all the other things that we know for sure they have been working on for many years.